Home » Stocks » Inhibitor Therapeutics

Inhibitor Therapeutics, Inc. (INTI)

Stock Price: $0.0550 USD -0.0030 (-5.17%)
Updated Oct 19, 2020 11:40 AM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 20.55M
Revenue (ttm) n/a
Net Income (ttm) -2.01M
Shares Out 373.64M
EPS (ttm) -0.01
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 19, 2020
Last Price $0.0550
Previous Close $0.0580
Change ($) -0.0030
Change (%) -5.17%
Day's Open 0.0550
Day's Range 0.0550 - 0.0550
Day's Volume 14,850
52-Week Range 0.0064 - 0.114

More Stats

Market Cap 20.55M
Enterprise Value 20.45M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 373.64M
Float 77.90M
EPS (basic) n/a
EPS (diluted) -0.01
FCF / Share -0.01
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 19,880
Short Ratio 0.07
Short % of Float 0.03%
Beta -0.25
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 76.91
Revenue n/a
Operating Income -2.02M
Net Income -2.01M
Free Cash Flow -1.83M
Net Cash 95,717
Net Cash / Share 0.00
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -107.61%
ROE n/a
ROIC 685.90%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (0)

Buy 0
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: n/a

Price Target

$3.50*
Low
3.50
Current: $0.0550
High
3.50
Target: 3.50
*Average 12-month price target from 1 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue----------
Operating Income-2.75-4.56-5.12-7.02-3.95-3.94-2.00-0.56-0.98-1.03
Net Income-2.73-4.55-5.10-7.00-3.95-3.98-1.840.19-0.23-1.00
Shares Outstanding37037036728923395.8817.9413.6512.66-
Earnings Per Share-0.01-0.01-0.01-0.02-0.02-0.04-0.100.01-0.02-0.10
Operating Cash Flow-2.71-3.71-2.91-3.76-2.26-1.30-1.22-0.460.07-0.17
Capital Expenditures--------1.37-
Free Cash Flow-2.71-3.71-2.91-3.76-2.26-1.30-1.22-0.461.44-0.17
Cash & Equivalents0.801.110.346.890.600.370.000.861.320.10
Total Debt------0.07-0.673.73
Net Cash / Debt0.801.110.346.890.600.37-0.070.860.66-3.63
Assets0.901.230.777.340.890.460.010.941.406.15
Liabilities3.431.200.600.310.460.400.781.071.775.75
Book Value-2.530.030.177.030.420.06-0.77-0.13-0.370.40
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Inhibitor Therapeutics, Inc.
Country United States
Employees 2
CEO Nicholas Jon Virca

Stock Information

Ticker Symbol INTI
Stock Exchange US OTC
Sector Healthcare
Industry Biotechnology
Unique Identifier OTCMKTS: INTI

Description

Inhibitor Therapeutics operates as a pharmaceutical development company that discovers, develops, and plans to commercialize therapeutics to inhibit the progression of cancerous and non-cancerous proliferation disorders in the United States. The company's Hedgehog signaling pathway is a primary regulator of cellular processes in vertebrates, including cell differentiation, tissue polarity, and cell proliferation. It focuses on developing its lead product, SUBA-Itraconazole, a patented oral formulation for prostate and lung cancer. The company was formerly known as HedgePath Pharmaceuticals, Inc. and changed its name to Inhibitor Therapeutics Inc. in August 2019. Inhibitor Therapeutics Inc. was founded in 1992 and is based in Tampa, Florida.